Radisys Introduces Programmable Media Analytics to Monetize 5G & Edge Cloud Applications
23.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced the addition of Engage Media Analytics within the acclaimed Engage Digital Platform (EDP). Engage Media Analytics is a comprehensive solution that provides Communication Service Providers (CSPs), System Integrators, and Enterprises with cost-effective low-code/no-code visual design tools to create Industry 4.0 applications with new AI-powered audio analytics and computer vision capabilities.
Engage Media Analytics’ application possibilities include notifying medical personnel when a patient in a wheelchair needs assistance or an elderly at-home patient has fallen from the bed; or identifying critical keywords or background sounds on an emergency call to augment the live agent discussion and help make life-saving decisions; detecting a fire in a factory, campus building, or other location and alerting emergency services personnel; monitoring retail shelves and combing customer identification, location, and live video to send money saving coupons to a frequent shopper’s phone as they near a location with promotional items; and many other Industry 4.0 services.
The Engage Media Analytics solution offers a unique combination of capabilities:
- Off-the-shelf models including people and object counting, object and sound detection and classification, and biometric authentication. Engage Media Analytics also supports model customization and new model creation.
- Ability to create trigger actions based on insights derived from the media stream whether through other communication capabilities in the EDP, including voice and video calling, creating an on-the-fly conference, sending alerts, and recording, as well as interworking with external systems for initiating business processes in enterprise workflow tools.
- Distributed deployment of services spanning public and private clouds, network edge infrastructure, and on enterprise premises, enabling applications that demand low latency, cost and bandwidth-efficient network utilization for local breakout, and ensuring data privacy and security.
Alan Quayle, Founder TADHack, TADSummit, said: “The programmable communications industry (CPaaS) is evolving from a focus on connectivity to understanding the content of communications through programmable media analytics. Actionable intelligence and compliance are important in delivering innovative new services. The all-in-one Engage Digital Platform delivers AI-based actionable intelligence that enables service providers to deliver business efficiencies for their customers' mission-critical applications.”
Radisys’ Engage Media Analytics can be deployed on distributed edge cloud and integrates with public or private 4G/5G RAN and core network functions such as Network Exposure Function (NEF), abstracting complexities for application developers to productize Industry 4.0 applications quickly and cost-effectively.
Al Balasco, Head of Media and Application Solutions, Radisys, said: “The convergence and simultaneous maturity of multiple technologies like AI-based computer vision, 5G, edge cloud, and programmable communications opens new opportunities for service providers and system integrators to collaborate with enterprises in their digital transformation. Engage Media Analytics lets service providers combine the advantages of the bandwidth, low latency, Internet of Things (IoT) connectivity, and edge cloud resources to monetize public and private 5G networks and deliver customized solutions like predictive surveillance in smart cities, remote monitoring of enterprise campuses, business workflow automation for product quality assurance, traffic monitoring, and more.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys’ Engage Digital Platform is an award-winning programmable communications platform. Radisys' capacity-based versus consumption-based licensing approach for all products in the Engage Digital Platform offers a truly disruptive economic model relative to alternative programmable communications solutions. It dramatically improves the total cost of ownership (TCO) savings to 70% and greater over competitive cloud-based programmable communications and video analytics solutions, allowing service providers to reap the benefits.
For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005336/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom